

# Chin B Eap

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2681224/chin-b-eap-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

240 papers	9,079 citations	54 h-index	83 g-index
250 ext. papers	10,070 ext. citations	3.9 avg, IF	5.65 L-index

#	Paper	IF	Citations
240	Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.. <i>BMC Psychiatry</i> , <b>2022</b> , 22, 342	4.2	0
239	Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> , 129, 26-35	3.1	1
238	The role of cytochrome P450 enzyme genetic variants in cannabis hyperemesis syndrome-A case report. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> , 129, 82-85	3.1	2
237	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. <i>World Journal of Biological Psychiatry</i> , <b>2021</b> , 22, 561-628	3.8	3
236	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 360	8.6	1
235	Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass. <i>Obesity Surgery</i> , <b>2021</b> , 31, 1353-1356	3.7	0
234	Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study. <i>Pharmacopsychiatry</i> , <b>2021</b> , 54, 279-286	2	0
233	Metabolomic alteration induced by psychotropic drugs: Short-term metabolite profile as a predictor of weight gain evolution. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 2544-2555	4.9	1
232	Investigating the Relations Between Caffeine-Derived Metabolites and Plasma Lipids in 2 Population-Based Studies. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 3071-3085	6.4	0
231	Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort.. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 756403	5	1
230	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , <b>2021</b> , 55,	2	11
229	A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1642-1653	3.8	1
228	Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication. <i>PLoS ONE</i> , <b>2020</b> , 15, e0242569	3.7	3
227	Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	2
226	Monitoring caffeine intake in children with a questionnaire and urine collection: a cross-sectional study in a convenience sample in Switzerland. <i>European Journal of Nutrition</i> , <b>2020</b> , 59, 3537-3543	5.2	1
225	The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2020</b> , 126, 444-447	3.1	1
224	Population biomonitoring of micronutrient intakes in children using urinary spot samples. <i>European Journal of Nutrition</i> , <b>2020</b> , 59, 3059-3068	5.2	

223	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 371-382	6.2	4
222	A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. <i>Drug Development Research</i> , <b>2020</b> , 81, 102-113	5.1	6
221	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 949-963	4.1	15
220	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2022-2032	3.8	2
219	Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 939-949	2.8	2
218	Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 238-246	8.7	4
217	Caffeine Consumption in Switzerland: Results from the First National Nutrition Survey MenuCH. <i>Nutrients</i> , <b>2019</b> , 12,	6.7	5
216	Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2019</b> , 9, 2045125319891386	4.9	3
215	Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , <b>2019</b> , 33, 1201-1222	6.7	10
214	Psychotropic drug-induced genetic-epigenetic modulation of CRTCL1 gene is associated with early weight gain in a prospective study of psychiatric patients. <i>Clinical Epigenetics</i> , <b>2019</b> , 11, 198	7.7	2
213	Genetic and clinic predictors of new onset diabetes mellitus after transplantation. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 53-64	3.5	6
212	Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2018</b> , 28, 258-265	2.9	11
211	The effect of a single dose of escitalopram on sensorimotor networks. <i>Brain and Behavior</i> , <b>2018</b> , 8, e009754	3.4	2
210	F44. AN ADD-ON TRIAL WITH N-ACETYL-CYSTEINE (NAC) IN EARLY PSYCHOSIS PATIENTS: TOWARDS BIOMARKER GUIDED TREATMENT. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S236-S236	1.3	78
209	Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 586-596	6.4	10
208	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 317-327	1.3	83
207	Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 219-229	4.9	14
206	Psychotropic Drug Prescription in Adolescents: A Retrospective Study in a Swiss Psychiatric University Hospital. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2018</b> , 28, 192-204	2.9	3

205	F227. PSYCHOLOGICAL TRAUMA OCCURRING DURING ADOLESCENCE IS ASSOCIATED WITH AN INCREASED RISK OF GREATER WAIST CIRCUMFERENCE IN EARLY PSYCHOSIS PATIENTS INDEPENDENTLY OF MEDICATION. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S310-S310	1.3	78
204	Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 573	5	3
203	CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 69-75	3.5	8
202	Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2017</b> , 1057, 101-109	3.2	11
201	Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study. <i>BMC Medical Genetics</i> , <b>2017</b> , 18, 76	2.1	13
200	Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs. <i>Gene</i> , <b>2017</b> , 628, 8-15	3.8	3
199	Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. <i>Pharmacogenetics and Genomics</i> , <b>2017</b> , 27, 464-472	1.9	4
198	Gender-specific alteration of energy balance and circadian locomotor activity in the <i>Crtc1</i> knockout mouse model of depression. <i>Translational Psychiatry</i> , <b>2017</b> , 7, 1269	8.6	10
197	Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 738	5.6	1
196	Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy. <i>Experimental and Clinical Psychopharmacology</i> , <b>2017</b> , 25, 353-362	3.2	4
195	Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 131, 233-245	3.5	12
194	Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 1521-1533	6.2	22
193	Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts. <i>Epigenomics</i> , <b>2016</b> , 8, 181-95	4.4	13
192	Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations. <i>PLoS ONE</i> , <b>2016</b> , 11, e0164443	3.7	6
191	Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. <i>Dialogues in Clinical Neuroscience</i> , <b>2016</b> , 18, 313-322	5.7	11
190	Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 547-557	1.9	7
189	Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 208-17	1.9	2
188	Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 90-2	1.7	9

187	Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population. <i>Nutrition and Metabolism</i> , <b>2016</b> , 13, 81	4.6	12
186	Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression. <i>Journal of Affective Disorders</i> , <b>2016</b> , 198, 43-9	6.6	15
185	Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 5472-5482	5.6	64
184	Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1486-1497	3.8	5
183	The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. <i>Molecular Psychiatry</i> , <b>2015</b> , 20, 1448-59	15.1	45
182	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 1259-72	6.2	35
181	Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 246-58	1.9	9
180	Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. <i>Journal of Chromatography A</i> , <b>2015</b> , 1420, 119-28	4.5	26
179	Severe manic episode associated with tramadol in a patient with recurrent depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 203-4	1.7	6
178	Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 544-52	1.7	5
177	Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolite excretions. <i>Hypertension</i> , <b>2015</b> , 65, 691-6	8.5	27
176	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 413-27	4.1	38
175	Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139155	3.7	11
174	Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, e1417-23	4.6	43
173	Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 95, 254-7	6.1	42
172	Quantification of typical antipsychotics in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2014</b> , 88, 36-44	3.5	33
171	Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 135-44	3.8	37
170	Blood pressure in relation to coffee and caffeine consumption. <i>Current Hypertension Reports</i> , <b>2014</b> , 16, 468	4.7	35

169	Serotonin toxicity after addition of mirtazapine to escitalopram. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 540-1	1.7	7
168	Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a nonfatal overdose during a suicide attempt. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 398-9	1.7	1
167	Substance Use in Adolescent Psychiatric Outpatients: Self-Report, Health Care Providers' Clinical Impressions, and Urine Screening. <i>Journal of Child and Adolescent Substance Abuse</i> , <b>2014</b> , 23, 1-8	0.6	1
166	Can valproic acid be an inducer of clozapine metabolism?. <i>Pharmacopsychiatry</i> , <b>2014</b> , 47, 89-96	2	39
165	Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. <i>Psychiatric Quarterly</i> , <b>2013</b> , 84, 329-35	4.1	5
164	Population pharmacokinetic study of memantine: effects of clinical and genetic factors. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 211-23	6.2	34
163	Influence of CRT1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population. <i>JAMA Psychiatry</i> , <b>2013</b> , 70, 1011-9	14.5	37
162	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 1007-18	3.8	25
161	Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. <i>Journal of Chromatography A</i> , <b>2013</b> , 1292, 160-72	4.5	59
160	Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 225-41	6.2	118
159	Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2013</b> , 77, 1-8	3.5	18
158	Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 289-98	1.7	19
157	Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 270-5	3.2	25
156	Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 84-93	1.9	38
155	Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 286-92	1.9	17
154	Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 171-82	1.6	25
153	Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2012</b> , 64-65, 16-25	3.5	34
152	Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. <i>Journal of Psychiatric Research</i> , <b>2012</b> , 46, 540-8	5.2	29



151	Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2012</b> , 885-886, 117-30	3.2	34
150	Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 622-9	1.7	21
149	Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 3283-92	5.6	45
148	Adherence to antidepressant treatment: what the doctor thinks and what the patient says. <i>Pharmacopsychiatry</i> , <b>2012</b> , 45, 204-7	2	12
147	Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 143-51	1.9	26
146	Arrestin2 influences the response to methadone in opioid-dependent patients. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 258-66	3.5	31
145	Quantification of nicotine, cotinine, trans-3-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2011</b> , 879, 3574-82	3.2	31
144	Simultaneous determination of antideementia drugs in human plasma for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 227-38	3.2	17
143	Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 117-25	6.1	70
142	Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 896-907	4.6	32
141	Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2011</b> , 879, 1544-50	3.3	19
140	La pharmacogénétique/pharmacogénomique en psychiatrie, perspectives théoriques et perspectives pour l'avenir. <i>Information Psychiatrique</i> , <b>2011</b> , 87, 697		
139	Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2011</b> , 37, 264-8	3.7	5
138	The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. <i>British Journal of Pharmacology</i> , <b>2010</b> , 160, 907-18	8.6	123
137	Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. <i>British Journal of Pharmacology</i> , <b>2010</b> , 160, 919-30	8.6	131
136	Lack of association between genetic polymorphisms of ARRB2 and alcohol dependence in a Caucasian population. <i>Alcohol and Alcoholism</i> , <b>2010</b> , 45, 590-1	3.5	5
135	The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2010</b> , 6, 953-65	5.5	21
134	Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 529-36		75

133	Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2009</b> , 877, 2301-7	3.2	17
132	Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 1113-20	2.8	14
131	Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 85, 485-94	6.1	94
130	Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2009</b> , 50, 1000-8	3.5	88
129	CYP3A5 and ABCB1 genes and hypertension. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 477-87	2.6	26
128	The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 877-83	1.9	93
127	ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. <i>Journal of Clinical Psychopharmacology</i> , <b>2009</b> , 29, 319-26	1.7	98
126	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 300-9	1.9	122
125	No influence of ABCB1 haplotypes on methadone dosage requirement. <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 83, 668-9; author reply 669-70	6.1	24
124	Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. <i>Pharmacological Research</i> , <b>2008</b> , 58, 344-7	10.2	77
123	Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2008</b> , 32, 1722-7	5.5	70
122	Brain dopamine response in human opioid addiction. <i>British Journal of Psychiatry</i> , <b>2008</b> , 193, 65-72	5.4	53
121	CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 474-82	3.2	105
120	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 689-99	3.2	57
119	Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 307-15	1.9	79
118	Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 511-22	3.2	40
117	Association of ABCB1 genetic variants with renal function in Africans and in Caucasians. <i>BMC Medical Genomics</i> , <b>2008</b> , 1, 21	3.7	12
116	Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression?. <i>Critical Care</i> , <b>2007</b> , 11, 119	10.8	10



115	Determination and distribution of clotiapine (Entumine) in human plasma, post-mortem blood and tissue samples from clotiapine-treated patients and from autopsy cases. <i>Forensic Science International</i> , <b>2007</b> , 170, 193-9	2.6	18
114	Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 719-28	6.1	204
113	Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2007</b> , 32, 641-9	2.2	37
112	Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2007</b> , 11, 123-8	2.4	1
111	In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. <i>Pharmacology</i> , <b>2007</b> , 80, 304-11	2.3	47
110	CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. <i>Hypertension</i> , <b>2007</b> , 49, 1007-14	8.5	53
109	Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 273-8	1.7	40
108	Time course of response to paroxetine: influence of plasma level. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2007</b> , 31, 892-900	5.5	10
107	Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. <i>Pharmacopsychiatry</i> , <b>2006</b> , 39, 150-2	2	13
106	Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. <i>Drug Safety</i> , <b>2006</b> , 29, 735-68	5.1	64
105	Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening. <i>Addictive Behaviors</i> , <b>2006</b> , 31, 1252-8	4.2	28
104	Risperidone-induced symptomatic hyperprolactinaemia in adolescents. <i>Journal of Clinical Psychopharmacology</i> , <b>2006</b> , 26, 167-71	1.7	16
103	Aripiprazole and suicidality. <i>International Clinical Psychopharmacology</i> , <b>2006</b> , 21, 125-6	2.2	7
102	Association of CYP3A5 genotypes with blood pressure and renal function in African families. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 923-9	1.9	36
101	Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. <i>Journal of Clinical Psychopharmacology</i> , <b>2006</b> , 26, 679-81	1.7	9
100	Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 97-112	3.8	138
99	Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 307-18	6.1	55
98	ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 668-81	6.1	194

97	Prevalence of methadone injection in three Swiss cities. <i>Presse Medicale</i> , <b>2005</b> , 34, 776-80	2.2	3
96	Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2005</b> , 29, 952-6	5.5	18
95	Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 539-43	3.2	74
94	Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 78, 593-604	6.1	184
93	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 60, 865-73	2.8	56
92	Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. <i>Psychopharmacology</i> , <b>2005</b> , 181, 751-60	4.7	78
91	Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. <i>International Journal of Neuropsychopharmacology</i> , <b>2005</b> , 8, 403-10	5.8	78
90	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , <b>2004</b> , 18, 559-66	4.6	5
89	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , <b>2004</b> , 18, 559-566	4.6	23
88	High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2004</b> , 8, 191-5	2.4	4
87	Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. <i>European Journal of Clinical Pharmacology</i> , <b>2004</b> , 60, 237-46	2.8	74
86	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. <i>European Journal of Clinical Pharmacology</i> , <b>2004</b> , 60, 231-6	2.8	69
85	Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 802, 339-45	3.2	37
84	Determination of human plasma levels of levo-alpha-acetylmethadol and its metabolites by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 805, 141-6	3.2	1
83	Death following acute poisoning by moclobemide. <i>Forensic Science International</i> , <b>2004</b> , 140, 101-7	2.6	11
82	Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 55-63	6.1	39
81	Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 214-9	1.7	83
80	High dose of depot risperidone in a nonresponder schizophrenic patient. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 673-4	1.7	13

79	Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 366-74	3.2	34
78	Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 283-90	1.7	27
77	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 255-60		27
76	Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 152-5	3.2	21
75	Methadone maintenance treatment and St. John's Wort - a case report. <i>Pharmacopsychiatry</i> , <b>2003</b> , 36, 35-7	2	68
74	Clinical outcome after trimipramine in patients with delusional depression - a pilot study. <i>Pharmacopsychiatry</i> , <b>2003</b> , 36, 12-7	2	30
73	Increase of oral methadone dose in methadone injecting patients: a pilot study. <i>Journal of Addictive Diseases</i> , <b>2003</b> , 22, 7-17	1.7	7
72	Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. <i>Pharmacogenetics and Genomics</i> , <b>2003</b> , 13, 39-47		84
71	Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 600-8	3.2	27
70	Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. <i>Addiction Biology</i> , <b>2003</b> , 8, 59-66	4.6	12
69	Identification of a novel splice-site mutation in the CYP1A2 gene. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 56, 341-4	3.8	42
68	Cytochrome P450A4 metabolic activity, methadone blood concentrations, and methadone doses. <i>Drug and Alcohol Dependence</i> , <b>2003</b> , 69, 205-11	4.9	33
67	Automated LC-MS method for the fast stereoselective determination of methadone in plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2003</b> , 41, 1615-21	5.9	20
66	Pharmacogenetics of chiral psychotropic drugs <b>2002</b> , 181-214		2
65	Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment. <i>Chirality</i> , <b>2002</b> , 14, 347-50	2.1	4
64	The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. <i>Pharmacopsychiatry</i> , <b>2002</b> , 35, 50-6	2	59
63	Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. <i>International Clinical Psychopharmacology</i> , <b>2002</b> , 17, 141-3	2.2	88
62	Very long half-life of paroxetine following intoxication in an extensive cytochrome P450D6 metabolizer. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 567-9	3.2	6

61	Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 211-5	1.7	59
60	Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. <i>European Neuropsychopharmacology</i> , <b>2002</b> , 12, 255-60	1.2	41
59	Enantiomers Potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. <i>European Neuropsychopharmacology</i> , <b>2002</b> , 12, 433-44	1.2	63
58	Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. <i>Clinical Pharmacokinetics</i> , <b>2002</b> , 41, 1153-93	6.2	406
57	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet, The</i> , <b>2002</b> , 359, 30-6	4.0	575
56	Pharmakokinetik und therapeutisches Monitoring von Antidepressiva <b>2002</b> , 37-50		
55	Enantiomeric antidepressant drugs should be considered on individual merit. <i>Human Psychopharmacology</i> , <b>2001</b> , 16, S85-S92	2.3	20
54	Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 228-31	3.2	20
53	Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 553-5	3.2	49
52	Cytochrome P450 2D6 genotype and methadone steady-state concentrations. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 229-34	1.7	86
51	Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P450 2D6 poor and extensive metabolizers. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 330-4	1.7	48
50	Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations. <i>Journal of Nervous and Mental Disease</i> , <b>2001</b> , 189, 798-9	1.8	1
49	Cytochrome P-450 activities in human and rat brain microsomes. <i>Brain Research</i> , <b>2000</b> , 855, 235-43	3.7	66
48	Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. <i>International Journal of Neuropsychopharmacology</i> , <b>2000</b> , 3, 55-60	5.8	17
47	Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. <i>Pharmacopsychiatry</i> , <b>2000</b> , 33, 112-5	2	25
46	Comment: opiate withdrawal symptoms induced by antiretroviral drugs. <i>Annals of Pharmacotherapy</i> , <b>2000</b> , 34, 1077-8	2.9	6
45	On the usefulness of therapeutic drug monitoring of methadone. <i>European Addiction Research</i> , <b>2000</b> , 6, 31-3	4.6	8
44	Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. <i>Drug and Alcohol Dependence</i> , <b>2000</b> , 61, 47-54	4.9	90

43	Efavirenz decreases methadone blood concentrations. <i>Aids</i> , <b>2000</b> , 14, 1291-2	3.5	38
42	Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 209-14	3.2	44
41	Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. <i>Drug and Alcohol Dependence</i> , <b>1999</b> , 55, 137-43	4.9	15
40	The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. <i>Pharmacogenetics and Genomics</i> , <b>1999</b> , 9, 55-60		94
39	Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 166-70	3.2	22
38	Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1998</b> , 64, 52-7	6.1	26
37	Determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , <b>1998</b> , 705, 139-44		9
36	Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. <i>Biomedical Applications</i> , <b>1998</b> , 719, 234-8		54
35	Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. <i>Journal of Chromatographic Science</i> , <b>1998</b> , 36, 365-71	1.4	96
34	Multiple and simultaneous phenotyping tests: beware of ascorbic acid when determining the mephenytoin (S)/(R) ratio. <i>Clinica Chimica Acta</i> , <b>1998</b> , 271, 105-7	6.2	
33	Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. <i>Pharmacopsychiatry</i> , <b>1998</b> , 31, 72	2	17
32	Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. <i>American Journal of Psychiatry</i> , <b>1998</b> , 155, 499-504	11.9	233
31	High interindividual variability of methadone enantiomer blood levels to dose ratios. <i>Archives of General Psychiatry</i> , <b>1998</b> , 55, 89-90		49
30	Steady state concentrations of the enantiomers of mianserin and desmethylnianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 7-13	3.2	21
29	Very high cytochrome P4501A2 activity and nonresponse to clozapine. <i>Archives of General Psychiatry</i> , <b>1998</b> , 55, 1048-50		44
28	Determination of the Enantiomers of Mianserin and its Metabolites in Plasma by Capillary Electrophoresis After Liquid-Liquid Extraction and On-Column Sample Preconcentration. <i>Journal of Chromatographic Science</i> , <b>1997</b> , 35, 315-320	1.4	21
27	Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. <i>Journal of Clinical Psychopharmacology</i> , <b>1997</b> , 17, 113-7	1.7	58
26	Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. <i>Pharmacopsychiatry</i> , <b>1996</b> , 29, 108-10	2	33

25	Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , <b>1996</b> , 50, 385-9	2.8	74
24	Two-step chromatographic purification of human plasma alpha(1)-acid glycoprotein: its application to the purification of rare phenotype samples of the protein and their study by chromatography on immobilized metal chelate affinity adsorbent. <i>Biomedical Applications</i> , <b>1996</b> , 678, 1-14		13
23	Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , <b>1996</b> , 682, 265-72		67
22	Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 322-31	6.1	56
21	Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. <i>Biomedical Applications</i> , <b>1996</b> , 686, 51-63		63
20	Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 570-2	3.2	30
19	Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. <i>Biomedical Applications</i> , <b>1995</b> , 669, 271-9		36
18	Determination of the enantiomers of mianserin, desmethybmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. <i>Chirality</i> , <b>1994</b> , 6, 555-63	2.1	19
17	Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , <b>1994</b> , 652, 97-103		6
16	Increased trimipramine plasma levels during fluvoxamine comedication. <i>European Neuropsychopharmacology</i> , <b>1994</b> , 4, 15-20	1.2	28
15	Probable metabolic interaction between methadone and fluvoxamine in addict patients. <i>Therapeutic Drug Monitoring</i> , <b>1994</b> , 16, 42-5	3.2	70
14	Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , <b>1993</b> , 616, 221-8		34
13	Artifacts in the analysis of thioridazine and other neuroleptics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>1993</b> , 11, 451-7	3.5	19
12	Klinische Relevanz pharmakogenetischer Phänotypisierungen <b>1993</b> , 658-663		
11	Plasma levels of trimipramine and metabolites in four patients: determination of the enantiomer concentrations of the hydroxy metabolites. <i>Therapeutic Drug Monitoring</i> , <b>1992</b> , 14, 380-5	3.2	20
10	Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. <i>Neuropsychobiology</i> , <b>1992</b> , 25, 214-20	4	14
9	Light-Induced Racemization. <i>Therapeutic Drug Monitoring</i> , <b>1991</b> , 13, 356-362	3.2	17
8	Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. <i>Biochemical Journal</i> , <b>1991</b> , 276 ( Pt 2), 343-7	3.8	45



7	Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions. <i>Clinica Chimica Acta</i> , <b>1991</b> , 203, 379-85	6.2	28
6	Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 47, 338-46	6.1	113
5	Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomuroid) variants. <i>Human Genetics</i> , <b>1989</b> , 84, 89-91	6.3	35
4	Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. <i>Journal of Pharmacy and Pharmacology</i> , <b>1988</b> , 40, 767-70	4.8	20
3	Isoelectric focusing of alpha-1 acid glycoprotein (orosomuroid) in immobilized pH-gradients with 8M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. <i>Electrophoresis</i> , <b>1988</b> , 9, 650-4	3.6	39
2	Orosomuroid (alpha-1 acid glycoprotein) phenotyping by use of immobilized pH gradients with 8 M urea and immunoblotting. A new variant encountered in a population study. <i>Human Genetics</i> , <b>1988</b> , 80, 183-5	6.3	25
1	Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1988</b> , 337, 220-4	3.4	21